Suppr超能文献

墨西哥的I型黏多糖贮积症:基于病例的综述。

Mucopolysaccharidosis Type I in Mexico: Case-Based Review.

作者信息

Cantú-Reyna Consuelo, Vazquez-Cantu Diana Laura, Cruz-Camino Héctor, Narváez-Díaz Yuriria Arlette, Flores-Caloca Óscar, González-Llano Óscar, Araiza-Lozano Carolina, Gómez-Gutiérrez René

机构信息

Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey 64710, Mexico.

Medical Department, Genomi-k, Monterrey 64060, Mexico.

出版信息

Children (Basel). 2023 Mar 30;10(4):642. doi: 10.3390/children10040642.

Abstract

INTRODUCTION

Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disease present in 1:100,000 newborns. Variants in the IDUA (alpha-L-iduronidase) gene decrease the enzyme activity for glycosaminoglycans metabolism. MPS I patients exhibit clinical manifestations that fall on the Hurler, Hurler-Scheie, and Scheie syndrome spectrum.

CASE PRESENTATION

We present a male Mexican patient with respiratory exacerbations requiring recurrent hospitalizations. He showed macrocephaly, coarse facies, hepatomegaly, umbilical hernia, and dorsal kyphosis. The sequencing of the IDUA gene revealed the following genotype: c.46_57del12/c.1205G>A. He received combined therapy with hematopoietic stem cell transplantation and enzyme replacement. Mexican case reports were analyzed to estimate the prevalence of the associated genetic variants.

CONCLUSION

Despite the challenges of managing this rare disease in Mexico, our patient benefited from the combined therapy. The discrete clinical manifestations and prompt evaluation by a geneticist were crucial in establishing a diagnosis, enabling an early intervention by a multidisciplinary team. The combination of ERT before and after HSCT provided health benefits to our patient.

摘要

引言

I型黏多糖贮积症(MPS I)是一种溶酶体贮积病,在新生儿中的发病率为1:100,000。艾杜糖醛酸酶(IDUA)基因的变异会降低糖胺聚糖代谢的酶活性。MPS I患者表现出属于Hurler综合征、Hurler-Scheie综合征和Scheie综合征谱系的临床表现。

病例报告

我们报告了一名患有呼吸加重症且需要反复住院治疗的墨西哥男性患者。他表现出巨头畸形、面容粗糙、肝肿大、脐疝和脊柱后凸。IDUA基因测序显示以下基因型:c.46_57del12/c.1205G>A。他接受了造血干细胞移植和酶替代的联合治疗。对墨西哥的病例报告进行了分析,以估计相关基因变异的患病率。

结论

尽管在墨西哥管理这种罕见疾病存在挑战,但我们的患者从联合治疗中受益。离散的临床表现以及遗传学家的及时评估对于确立诊断至关重要,从而使多学科团队能够进行早期干预。造血干细胞移植前后的酶替代疗法相结合为我们的患者带来了健康益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cab/10136708/0ace8d25bc0c/children-10-00642-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验